A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE) (NCT04803058) | Clinical Trial Compass
Active — Not RecruitingPhase 2
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
United States, South Korea18 participantsStarted 2022-12-14
Plain-language summary
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Able to understand the study requirements and provide written informed consent before any study assessment is performed
* Male or female patients ≥ 18 to 65 years of age
* Recipient of a renal transplant from a non-human leukocyte antigen (HLA)-identical but at least haploidentical, ABO compatible living donor
Key Exclusion Criteria:
* Women of child-bearing potential, unless willing to comply with the use of highly effective methods of contraception as defined by the protocol
* A history of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix
* Recipient with anti-HLA donor-specific antibody (DSA)
What they're measuring
1
The safety, tolerability and activity of a Siplizumab-based conditioning regimen to induce renal allograft tolerance